| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10750757 | Biochemical and Biophysical Research Communications | 2015 | 23 Pages |
Abstract
Targeting the sigma-2 receptor with a cytotoxic payload was effective in all the three cell lines evaluated and provides the proof of concept for future development of a therapeutic platform for the treatment of TNBC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Mehran Makvandi, Estifanos D. Tilahun, Brian P. Lieberman, Redmond-Craig Anderson, Chenbo Zeng, Kuiying Xu, Catherine Hou, Elizabeth S. McDonald, Daniel A. Pryma, Robert H. Mach,